ATTOAttovia Therapeutics

Median target
$42
calls from the last 12 months
Implied return
+84.8%
median target vs. price
Coverage
4 analysts · 4 calls
updated in the last 12 months
Consensus
4/0/0+4 net
Buy / Hold / Sell

Which analysts are behind ATTO's consensus?

See every current rating, price target and the analysts' track records for Attovia Therapeutics — plus the full analyst rankings, firm analytics and screener.

The consensus above reflects 4 analysts with calls on ATTO updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.

ATTO elsewhere on AnalystEdge

The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.

Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)

DateSourceWhoActionDetailAmount
2026-08-06InsidersFrazier Life Sciences Xi, L.P. +210% ownerInsider purchase588.2K sh @ $17.00$10.0M
2026-08-06InsidersGoldman Sachs Group Inc +7Insider purchase500.0K sh @ $17.00$8.5M
2026-08-06InsidersWalsh ColinDirectorInsider purchase500.0K sh @ $17.00$8.5M
2026-08-06InsidersWalsh ColinDirectorInsider purchase500.0K sh @ $17.00$8.5M
2026-08-06InsidersGoldman Sachs Group Inc +7Insider purchase500.0K sh @ $17.00$8.5M
2026-08-06InsidersRedmile Group, Llc +210% ownerInsider purchase400.0K sh @ $17.00$6.8M
2026-08-06InsidersVenbio Global Strategic Fund I10% ownerInsider purchase382.4K sh @ $17.00$6.5M
2026-08-06InsidersSanofi10% ownerInsider purchase300.0K sh @ $17.00$5.1M
2026-08-06InsidersRedmile Group, Llc +210% ownerInsider purchase200.0K sh @ $17.00$3.4M
2026-08-05InsidersWalsh ColinDirectorInsider purchase85.0K sh @ $21.00$1.8M

More: insider activity · executive branch · trending